Herpes Simplex Virus (HSV-2) is a sexually transmitted virus which is a major cause of genital herpes (GH). Although most individuals infected with HSV-2 have minimal signs of infection, the disease is life-long and in some, causes considerable emotional and physical distress. Individuals asymptomatically infected with HSV-2 can continue to transmit virus making its containment at the public health level extremely challenging.
Vaccine manufacturers have pursued the development of prophylactic (PX) HSV vaccines albeit with little success to date (note: GSK’s Simplirix). Mathematical modelling has indicated that mass vaccination with a HSV vaccine that can prevent the establishment of viral latency and shedding could substantial reduce disease burden and economic cost. Sanofi Pasteur is clinically testing a replication-defective mutant virus, HSV529.
This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of a PX HSV vaccines across major Western markets + BRIC-M to 2040. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing, and penetration estimates. LO/BASE/HI target product profile (TPP) pricing scenarios are included which examine the uptake of vaccines across successive population groups. A detailed review is also included on latest trends in disease epidemiology/dynamics/competitive environment.